EVIO (OTCQB: EVIO) this morning announced that it has signed a non-binding Letter of Intent (“LOI”) to acquire 60% of C3 Labs, LLC. C3 Labs is located in Berkeley, CA, which accelerates the company’s intent to expand into Northern California prior to the anticipated increase in demand for analytical testing services. Subject to customary closing conditions, the transaction is expected to close in the first quarter of 2018. “C3 Labs been serving the cannabis industry for years, providing product formulation, research and development services that aligns with EVIO’s longer term strategy to expand our scope of services. We are working to close this transaction in an expeditious manner to begin serving the California market by first quarter 2018,” EVIO CEO William Waldrop stated in the news release.
To view the full press release, visit http://cnw.fm/7KtaP
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com